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INTRODUCTION
1. Background
Heart failure is associated with a variety of clinical symptoms that re-
sult from a structural or functional disability, and a reduced capacity to 
pump blood into and out of the ventricles [1]. Advances in medical tech-
nologies mean that the causes of heart failure associated with uncontrol-
lable hypertension and ischemic heart diseases, including myocardial 
infarction, valvular heart disease, and dilated cardiomyopathy, can be 
treated successfully. Despite successful treatment, the number of patients 
with long-term chronic heart failure has increased every year, and an ag-
ing population and the high rates of hypertension and diabetes mellitus 
have augmented this phenomenon [2]. Approximately 26 million indi-
viduals worldwide and 1 million individuals in Korea suffer from heart 
failure, and these numbers are expected to increase by 25.0% by 2030 [3-
5]. Heart failure is a cause of hospitalization in the USA and Europe, re-
sulting in over 1 million admissions [5]. In Korea, heart failure frequent-
ly leads to hospitalization and high treatment costs which are more than 
800 billion won per year [4].
Patients with heart failure experience physical symptoms, including 
fatigue, dyspnea, and generalized edema, depending on the condition’s 
severity. These physical symptoms can have psychological effects, for ex-
ample, anxiety, depression, and reduced self-efficacy, which can hinder 
daily activities, work, and a person’s social life [6]. Heart failure is diffi-
cult to cure, and its characteristics often include recurrent cycles of dete-
rioration and improvement. Consequently, rehospitalization rates con-
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tinue to rise, and they approach 30% within 60-90 days of discharge [7]. 
This negatively affects a patient’s quality of life, and it increases the bur-
den on families and other caregivers [6]. Hence, it is an important social 
and economic issue [3]. 
Most patients have difficulties recognizing the signs and symptoms of 
heart failure, because the symptoms are unspecific and they are often 
mistaken for normal changes associated with aging or comorbidities [6, 
8]. Failing to recognize the early symptoms and to seek treatment can re-
sult in more severe disease and hospitalization, because of delays associ-
ated with symptom management and reporting the symptoms to health 
care providers [9]. Consequently, treatment and recovery are delayed, be-
cause help was not sought until the symptoms were more severe. Delay-
ing treatment can lower the physical, psychological, and social aspects of 
a patient’s quality of life. Therefore, it is essential to understand the indi-
vidual clinical factors and indicators involved to facilitate the recognition 
of differences among patients with heart failure and to enable a systemat-
ic approach towards assessing the symptoms to be followed [10]. 
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is secreted 
by the heart’s ventricles in response to volume expansion and the pres-
sure load [11]. The serum NT-proBNP test is recommended as a diag-
nostic tool for heart failure by the American Heart Association [12]. 
Therefore, this test is widely used as a screening and/or diagnostic tool 
for patients with heart failure. Moreover, NT-proBNP is a reliable bio-
marker for grading the severity of heart failure and for predicting the re-
admission and mortality risks in patients with heart failure [13]. The re-
sults from previous studies have shown that the NT-proBNP levels in-
crease in normal individuals in association with being female and older, 
which indicates that the cut-off levels should be stratified according to 
age and sex [14, 15].
Adhering to self-care management protocols is an important aspect 
of heart failure treatment [18, 20, 23]. The findings from a previous study 
that investigated self-care and the NT-proBNP levels indicated that bet-
ter self-care management was associated with reduced NT-proBNP lev-
els [16]. This study’s findings also showed that self-care maintenance, 
which included adherence behaviors that maintained physiologic ho-
meostasis, self-care management that involved symptom evaluation and 
treatment, and self-care confidence that assessed a patient’s perceived 
ability to engage in the self-care process, may reduce myocardial stress; 
however, the potential correlates that were pertinent to patients with 
heart failure with physical symptom experiences were not explored. De-
spite the significance of NT-proBNP as a biomarker for patients with 
heart failure, the relationships between NT-proBNP and self-care behav-
iors and physical symptom experiences have rarely been investigated.
Identifying the relationships between a biomarker for heart failure 
and associated factors, including self-care and physical symptom experi-
ences, will help nurses to recognize the differences between individual 
patients with heart failure and to consider symptom management strate-
gies for their patients. Consequently, efficient management of and ap-
propriate self-care among patients with risk factors may lead to symp-
tom reductions and, ultimately, to positive clinical outcomes. Therefore, 
determining the relationships between the NT-proBNP levels and the 
relevant factors could enable differences in the NT-proBNP levels to be 
recognized, based on the characteristics of patients with heart failure, 
and provide a more comprehensive understanding of the symptoms. 
2. Purpose
The purpose of this study was to identify the patients’ characteristics, 
self-care behaviors, and physical symptom experiences in association 
with NT-proBNP, and to determine whether or not the NT-proBNP lev-
els differed among the factors investigated.
METHODS
1. Study Design 
This cross-sectional study aimed to examine the relationships be-
tween the NT-proBNP levels and related factors of patients with heart 
failure. The study utilized a convenience sample of adult outpatients and 
inpatients who attended a cardiology department in a tertiary hospital 
in Seoul, Korea. 
2. Setting and Study Sample
The clinical data were extracted from the electronic medical records 
(EMRs) of 154 patients with heart failure who attended a tertiary medi-
cal center. The general rule for calculating the sample size for multino-
mial logistic regression is a minimum ratio of 10 cases to each indepen-
dent variable, with a minimum sample size of 100 or 50 [17]. In this 
study, 12 independent variables, including age and sex, were incorporat-
ed into the multivariate models. The sample size to the number of inde-
pendent variables ratio was 12.8 to 1, which was greater than the mini-
mum ratio required. 
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Patients who were diagnosed with heart failure and were aged 18 
years or older, those who could communicate without any problems, 
and those with a stable hemodynamic status were included in the study. 
Patients who had undergone heart transplantations after being diag-
nosed with heart failure, those who had temporary heart failure with 
clearly defined causes, such as sepsis, anemia, or thyrotoxicosis, patients 
with normal left ventricular ejection fractions (LVEFs) (> 60%), and 
those with acute aortic dissections and idiopathic pulmonary hyperten-
sion were excluded from the study. 
3. Instruments
1)SociodemographicandClinicalData
The patients’ sociodemographic data were obtained by using a ques-
tionnaire that gathered data about the patient’s sex, age, marital status, 
education, employment status, and monthly income. The patients’ clini-
cal data were extracted from the patients’ EMRs, and they included data 
that described the New York Heart Association (NYHA) functional 
classification (FC) that graded the severity of the functional limitations 
associated with physical activity, the cause of heart failure, the LVEF, the 
presence of arrhythmias, the types and numbers of prescribed medica-
tions, the heart surgery and percutaneous coronary intervention histo-
ries, the comorbidities, the numbers of emergency room visits and re-
hospitalizations within 1 year, and the NT-proBNP level. The NYHA 
FC places patients in one of four categories; Class I, II, III, and IV mean-
ing ‘No symptoms of heart failure’, ‘Symptoms with moderate exertion’, 
‘Symptoms with minimal exertion’, and ‘Symptoms at rest’ respectively.
2)Self-CareBehaviors
The self-care behaviors were measured using the nine-item European 
Heart Failure Self-care Behavior (EHFScB-9) scale, an instrument that 
was developed for patients with heart failure by Jaarsma et al. [21] and 
that was translated, reverse-translated, and expert-verified by Son et al. 
[20]. The EHFScB-9 scale includes items that address multiple compo-
nents associated with self-care behaviors for heart failure, including 
weight measurements, reporting to a healthcare provider when body 
weight increases, fluid restrictions, consumption of a low-sodium diet, 
and compliance with prescribed medicines. The patients responded to 
the questionnaire using a five-point Likert scale with answers that 
ranged from 1=“completely disagree” to 5 =“completely agree”. The 
overall self-care behavior score was calculated from the means of all of 
the questions. A higher score indicated better self-care behaviors. The 
EHFScB-9 scale showed reliability in the study by Jaarsma et al. [21] 
(Cronbach’s α = 0.85) and in this study (Cronbach’s α = 0.65). Content 
validity and construct validity were established by Jaarsma et al. [21].
3)PhysicalSymptomExperiences
The physical symptom experiences caused by heart failure were mea-
sured using parts of the instrument developed by Riegel et al. [18] and 
modified by Song et al. [19]. The instrument is based on a four-point 
Likert scale, and it consists of 10 physical symptom items, including dys-
pnea, leg/ankle edema, anorexia, and fatigue. The instrument was modi-
fied by our research team to assess the symptoms, and to report the fre-
quency and intensity of each symptom separately. The patients respond-
ed to the questionnaire using the four-point Likert scale, and the re-
sponses ranged from “none” (0 points) to “severe” (4 points) for both fre-
quency and intensity; therefore, the mean of the two scores for each 
symptom ranged from 0 to 4. The overall physical symptom experiences 
score was calculated from the means of the scores for each symptom. 
The scale showed reliability in a previous study (Cronbach’s α = 0.84) 
[20] and in this study (Cronbach’s α = 0.85).
4. Data Collection 
The data were collected from October 2013 to November 2013 from 
heart failure outpatients and inpatients who attended the circulatory in-
ternal medicine and cardiology departments at Samsung Medical Cen-
ter, which is a tertiary medical center in Seoul, Korea. The self-adminis-
tered survey questionnaires and the EMRs were used to collect the data.
5. Data Analyses 
A total of 154 patients were included in the final analyses, with a 91% 
rate of return. The data collected were encoded and processed into sta-
tistical data using IBM®SPSS® software, version 20.0 (IBM Corporation, 
Armonk, NY, USA), and all of the analyses were carried out using a sig-
nificance level of p< .05. The sociodemographic and clinical character-
istics of the patients and the major variables were analyzed using univar-
iate analysis for inclusion in the regression model to examine related fac-
tors to NT-proBNP groups. The continuous variables, such as self-care 
behaviors and physical symptom experiences were anaylzed using an 
analysis of variance (ANOVA). And the categorical variables, such as 
NYHA classification, the cause of heart failure, the LVEF, the presence 
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of arrhythmias, the types and numbers of prescribed medications, the 
history of heart surgery and percutaneous coronary intervention histo-
ries, the comorbidities, the numbers of emergency room visits and re-
hospitalizations within 1 year were analyzed using Pearson’s chi-square 
test. The Scheffé post-hoc test was used for multiple-comparison for the 
ANOVA results. The previous studies have suggested that cut-off levels 
could be determined by stratifying the patients according to age, sex, 
and renal function [14, 15]. However, these cut-off values could not be 
used in this study, because the number of patients in some groups was 
too small. Furthermore, the distribution of the NT-proBNP levels was 
skewed, therefore, the frequencies in each group were disproportionate. 
Thus, we divided the patients into three equal groups based on the NT-
proBNP levels, i.e. tertiles. The significant variables identified in the uni-
variate analysis were included as independent variables and the three 
NT-proBNP groups were included as dependent variables in the multi-
nomial logistic regression. The multinomial logistic regression was ad-
justed for age and sex.
6. Ethical Considerations
This study was approved by Samsung Medical Center’s Institutional 
Review Board (Approval number: 2013-09-049-001). The research ob-
jectives, the methods, and the study’s duration were explained to the pa-
tients, and the patients were provided with detailed information regard-
ing their participation in the research. 
RESULTS
1.  Overall Sociodemographic and Clinical Characteristics of 
the Patients 
The patients’ mean ± standard deviation (SD) age was 60.8 ± 15.4 
years, and 91 patients (59.1%) were male. Most of the patients were mar-
ried (107 patients; 69.5%), and 54 (35.1%) patients were employed (Table 
1). Sixty-three patients (40.9%) had arrhythmias, and most of the patients 
(107 patients; 69.5%) were categorized as NYHA classes I or II. The mean
± SD number of prescribed medications was 5.1± 2.3. One-third of the 
participants (57 patients; 37.0%) had been hospitalized more than once 
within the previous year, because of heart failure, and 41 patients (26.6%) 
had visited the emergency room at least once within the previous year. 
The patients’ mean ± SD LVEF was 44.8± 17.7%. The most frequent co-
morbidity was diabetes (38 patients; 24.7%) (Table 2). The distribution of 
the NT-proBNP levels was skewed, and the median NT-proBNP level 
was 702.1 pg/mL. The patients were divided into three groups based on 
Table 1. Sociodemographic Characteristics of the N-Terminal Pro-B-Type Natriuretic Peptide Groups  (N = 154)
Characteristic n (%)
Low group (n = 52) Mid group (n = 51) High group (n = 51)
χ² p
n (%) n (%) n (%)
Sex 1.907 .385
   Male 91 (59.1) 28 (53.8) 29 (56.9) 34 (66.7)
   Female 63 (40.9) 24 (46.2) 22 (43.1) 17 (33.3)
Age (year), Mean ± SD 60.82 ± 15.43 10.369 .035
   < 50 35 (22.7) 15 (28.8) 13 (25.5) 7 (13.7)
   50-65 52 (33.8) 22 (42.3) 11 (21.6) 19 (37.3)
   > 65 67 (43.5) 15 (28.8) 27 (52.9) 25 (49.0)
Spouse 2.751 .253
   Yes 107 (69.5) 32 (61.5) 39 (76.5) 36 (70.6)
   No 47 (30.5) 20 (38.5) 12 (23.5) 15 (29.4)
Education 0.793 .992
   ≤ Elementary school 35 (22.7) 10 (19.2) 12 (23.5) 13 (25.5)
   Middle school 20 (13.0) 7 (13.5) 6 (11.8) 7 (13.7)
   High school 46 (29.9) 16 (30.8) 15 (29.4) 15 (29.4)
   ≥ College 53 (34.4) 19 (36.5) 18 (35.3) 16 (31.4)
Employment status 13.891 .001
   Employed 54 (35.1) 26 (50.0) 20 (39.2) 8 (15.7)
   Unemployed 100 (64.9) 26 (50.0) 31 (60.8) 43 (84.3)
Monthly income (1,000 won) 3.52 .172
   < 2,000 53 (34.4) 18 (34.6) 13 (25.5) 22 (43.1)
   ≥ 2,000 101 (65.6) 34 (65.4) 38 (74.5) 29 (56.9)
SD = Standard deviation.
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their NT-proBNP levels, as follows: Low: < 380 pg/mL; Mid: ≥ 380-
< 1289 pg/mL; and High: ≥ 128998 pg/mL. 
2.  Sociodemographic and Clinical Characteristics of the N-Terminal 
Pro-B-Type Natriuretic Peptide Groups
The patients in the High group were older than those in the Mid and 
Low groups (χ² =10.369; p= .035), and those in the Low group were more 
likely to be employed (χ² =13.891; p= .001) (Table 1). A high NT-proBNP 
level was associated with a higher incidence of arrhythmia (χ² =27.063; 
p< .001), a higher NYHA FC (χ² =30.661; p< .001), the administration of 
a higher number of medicines (χ² =18.808; p= .001), more frequent read-
missions (χ² =13.647; p= .001), and more frequent visits to the emergency 
room within the previous year (χ² =16.368; p< .001). The LVEF was sig-
nificantly associated with the NT-proBNP level, and patients in the High 
group were more likely to have lower LVEFs compared with those in the 
Mid and Low groups (χ² =16.880; p< .001) (Table 2).
3.  Self-care Behavior and Physical Symptom Experiences Scores 
for the N-Terminal Pro-B-Type Natriuretic Peptide Groups
The average overall scores for the self-care behaviors ranged from 1.8 
Table 2. Clinical Characteristics of the N-Terminal Pro-B-Type Natriuretic Peptide Groups  (N = 154)
Characteristic n (%)
Low group (n = 52) Mid group (n = 51) High group (n = 51)
χ² p
n (%) n (%) n (%)
Cause of heart failure 1.582 .453
   Ischemic 33 (21.4) 12 (23.1) 8 (15.7) 13 (25.5)
   Non-ischemic 121 (78.6) 40 (76.9) 43 (84.3) 38 (74.5)
Arrhythmias 27.063 < .001
   Yes 63 (40.9) 7 (13.5) 24 (47.1) 32 (62.7)
   No 91 (59.1) 45 (86.5) 27 (52.9) 19 (37.3)
NYHA FC 30.661 < .001
   Class I or II 107 (69.5) 45 (86.5) 41 (80.4) 21 (41.2)
   Class III 34 (22.1) 6 (11.5) 8 (15.7) 20 (39.2)
   Class IV 13 (8.4) 1 (1.9) 2 (3.9) 10 (19.6)
History of heart surgery 3.833 .147
   Yes 19 (12.3) 4 (7.7) 5 (9.8) 10 (80.4)
   No 135 (87.7) 48 (92.3) 46 (90.2) 41 (19.6)
History of PCI 2.045 .360
   Yes 22 (14.3) 7 (13.5) 5 (9.8) 10 (19.6)
   No 132 (85.7) 45 (86.5) 46 (90.2) 41 (80.4)
BMI (kg/m2) 4.813 .307
   < 18.5 8 (5.2) 2 (3.8) 2 (3.9) 4 (7.8)
   18.5-24.9 89 (57.8) 28 (53.8) 27 (52.9) 34 (66.7)
   > 25 57 (37.0) 22 (42.3) 22 (43.1) 13 (25.5)
Number of medicines,  Mean ± SD 5.05 ± 2.29 18.808 .001
   1-3 38 (24.8) 19 (36.5) 15 (29.4) 4 (7.8)
   4-6 73 (47.4) 26 (50.0) 23 (45.1) 24 (47.1)
   ≥ 7 43 (27.9) 7 (13.5) 13 (25.5) 23 (45.1)
Rehospitalization within 1 year 13.647 .001
   Yes 57 (37.0) 12 (23.1) 16 (31.4) 22 (43.1)
   No 97 (63.0) 40 (76.9) 35 (68.6) 29 (56.9)
ER visits within 1 year 16.368 < .001
   Yes  41 (26.6) 8 (15.4) 9 (17.6) 24 (47.1)
   No 113 (73.4) 44 (84.6) 42 (82.4) 27 (52.9)
LVEF (%), Mean ± SD 44.77 ± 17.65 16.88 < .001
   < 45% 73 (47.4) 17 (32.7) 20 (39.2) 36 (70.6)
   ≥ 45% 81 (52.6) 35 (67.3) 31 (60.8) 15 (29.4)
Comorbidities 9.185 .010
   Yes 62 (40.3) 15 (28.8) 18 (35.3) 29 (56.9)
   No 92 (59.7) 37 (71.2) 33 (64.7) 22 (43.1)
NYHA FC = New York Heart Association functional classification; PCI = Percutaneous coronary intervention; BMI = Body mass index; SD = Standard deviation; ER = Emergency 
room; LVEF = Left ventricular ejection fraction.
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to 4.8, which was based on a five-point scale, the average score was 3.5 ±
0.5, and there were no significant differences among the NT-proBNP 
groups. The highest scored item was “I take my medication as pre-
scribed” and the lowest scored item was “I limit the amount of fluids” 
(Table 3). The physical symptom experiences scores ranged from 0 to 4, 
and the average score was 1.2 ± 0.7. The average scores for symptom fre-
quency and symptom intensity were 1.2 ± 0.7 and 0.9 ± 0.6, respectively. 
Approximately 85.1% of the patients reported that they experienced “fa-
tigue”, which was scored with the highest frequency and intensity. The 
patients in the High group had higher scores for physical symptom ex-
periences (F =21.635, p< .001). All of the physical symptom experiences 
scores, except for those for “sleep disturbance” and “chest pain or chest 
tightness”, were significantly higher in the High group (Table 3). There 
were no differences between the Low and the Mid groups with respect 
to the physical symptom experiences scores. 
Table 3. Self-care Behavior and Physical Symptom Experiences Scores in the N-Terminal Pro-B-Type Natriuretic Peptide Groups (N = 154)
Characteristic
All cases (n = 154) Low groupa (n = 52) Mid groupb (n = 51) High groupc (n = 51)
F p
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Self-care behavior 3.49 ± 0.53 3.47 ± 0.50 3.51 ± 0.57 3.47 ± 0.52 0.106 .900
Physical symptom experiences 1.22 ± 0.74 0.83 ± 0.50 0.98 ± 0.73 1.65 ± 0.77 21.352a,b < c < .001
   Fatigue 2.09 ± 1.16 1.89 ± 1.13 1.91 ± 1.19 2.46 ± 1.08 4.136a < c .018
   Dyspnea during activities 1.69 ± 1.26 1.29 ± 1.00 1.42 ± 1.34 2.37 ± 1.15 13.141a,b < c < .001
   Sleep disturbance 1.37 ± 1.28 1.26 ± 1.19 1.21 ± 1.32 1.65 ± 1.30 1.84 .162
   Chest pain or chest tightness 1.13 ± 1.08 0.96 ± 0.95 1.06 ± 1.14 1.38 ± 1.13 2.148 .120
   Anorexia 1.10 ± 1.26 0.56 ± 0.93 0.96 ± 1.19 1.78 ± 1.32 14.947a,b < c < .001
   Leg/ankle edema 1.03 ± 1.19 0.74 ± 1.01 0.86 ± 1.13 1.48 ± 1.31 6.036a,b < c .003
   Nausea 1.00 ± 1.15 0.77 ± 0.98 0.84 ± 1.11 1.40 ± 1.26 4.86a,b < c .009
   Dyspnea while lying 0.80 ± 1.13 0.32 ± 0.59 0.57 ± 0.91 1.52 ± 1.38 20.16a,b < c < .001
   Dyspnea while resting 0.70 ± 1.00 0.32 ± 0.57 0.58 ± 0.86 1.22 ± 1.24 12.754a,b < c < .001
   Dyspnea while sleeping 0.59 ± 1.02 0.18 ± 0.50 0.39 ± 0.73 1.22 ± 1.34 17.86a,b < c < .001
Table 4. Multinomial Logistic Regression for the N-Terminal Pro-B-Type Natriuretic Peptide Groups*  (N = 154) 
Predictor
Low group vs. High group (reference group) Mid group vs. High group (reference group)
AOR 95% CI AOR 95% CI
Employed (reference group: no)
   Yes 5.16 (1.07-24.78) 4.90 (1.20-20.08)
Arrhythmia (reference group: no)
   Yes 0.04 (0.01-0.18) 0.38 (0.12-1.25)
NYHA FC (reference group: I or II)
   Class III 0.59 (0.09-3.80) 0.32 (0.07-1.48)
   Class IV 1.00 (0.04-25.16) 0.22 (0.02-2.76)
Number of medicines (reference group: ≥ 1-3)
   4-6 1.30 (0.21-7.94) 0.39 (0.08-2.03)
   7 1.38 (0.17-11.40) 0.66 (0.11-3.98)
Rehospitalized within 1 year (reference group: no)
   Yes 1.07 (0.22-5.12) 1.67 (0.41-6.79)
ER visited within 1 year (reference group: no)
   Yes 1.00 (0.18-5.44) 0.48 (0.11-2.13)
LVEF (reference group: < 45%)
   ≥ 45% 9.44 (2.21-40.27) 2.59 (0.74-9.06)
Comorbidity (reference group: no)
   Yes 0.19 (0.05-0.75) 0.30 (0.09-1.01)
Self-care 1.02 (0.32-3.25) 0.89 (0.32-2.48)
Physical symptom experiences 0.13 (0.03-0.50) 0.35 (0.12-1.03)
*Age and sex were adjusted.      
AOR = Adjusted odds ratio; CI = Confidence interval; NYHA FC = New York Heart Association functional classification;  ER = Emergency room; LVEF = Left ventricular 
ejection fraction.    
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4.  Factors Associated With the N-Terminal Pro-B-Type Natriuretic 
Peptide Level 
The significant variables identified by the univariate analysis were in-
cluded as the independent variables and the NT-proBNP groups were 
included as the dependent variables in the multinomial logistic regres-
sion. Age and sex were the confounding factors, and self-care was added 
as an independent variable, because it was a major factor in this study. 
The regression analysis was preceded by Pearson’s correlation to identify 
multicollinearity between the independent variables. The correlation 
coefficient was 0.02-0.60, which indicated that independence was main-
tained between the variables that were considered to be independent 
during this research. 
The High group was used as the reference group, and the adjusted odds 
ratios (ORs) for age, sex, the employment status, arrhythmias, the NYHA 
FC, the number of medicines, rehospitalizations within 1 year, emergency 
room visits within 1 year, the LVEF, comorbidities, self-care behaviors, and 
the physical symptom experiences were used in the final model (Table 4). 
Compared with the patients in the High group, the patients in the Low 
group were 5.16-times more likely to be employed (95% confidence interval 
[CI] =1.07-24.78) and those in the Mid group were 4.90-times more likely 
to be employed (95% CI =1.20-20.08). The occurrence of arrhythmias was 
lower in the Low group compared with the High group (OR, 0.04; 95% 
CI = 0.01-0.18). Compared with the patients in the High group, the patients 
in the Low group were 9.44-times more likely to have a higher LVEF (≥
45%) than a lower LVEF (<45%) (95% CI =2.21-40.27) and they were less 
likely to have comorbidities (OR, 0.19; 95% CI = 0.05-0.75). The patients in 
the Low group experienced fewer physical symptoms compared with the 
patients in the High group (OR, 0.13; 95% CI = 0.03-0.50).
DISCUSSION
This study examined the relationships between the patients’ NT-
proBNP levels and their sociodemographic and clinical characteristics, 
self-care behaviors, and physical symptom experiences. 
The patients in the High group were older than those in the Mid and 
Low groups. Previous studies’ findings have demonstrated that age and 
being female independently predict NT-proBNP levels in the normal 
range [14-16]; therefore, the NT-proBNP levels should be stratified ac-
cording to age and sex to determine the cut-off values for patients. 
There were statistically significant differences among the NT-proBNP 
groups with respect to several clinical factors. We determined that ar-
rhythmias, a higher NYHA class, a higher number of medicines, rehos-
pitalization, emergency room visits, a lower LVEF, and comorbidities 
were significantly associated with high NT-proBNP levels, which con-
curs with the findings from other studies on patients with heart failure 
[14, 16, 22]. 
Patients in the High group were more likely to have higher physical 
symptom experiences scores, but we were unable to identify a relation-
ship between NT-proBNP and self-care behaviors. The results from a 
previous study [23] suggested that patients who implemented better self-
care behaviors reduced their symptoms and that the tendency of those 
with more severe symptoms to implement better self-care behaviors was 
counterproductive.  Therefore, we speculate that better self-care may 
have led to lower physical symptom experiences scores in our study, 
which could lead to lower biomarker levels. 
Multinomial logistic regression showed that compared with the pa-
tients in the High group, the patients in the Low and Mid groups were 
more likely to be employed. Compared with the patients in the High 
group, more patients in the Low group did not have arrhythmias, low 
LVEFs (<45%), or any comorbidities, and they had lower physical symp-
tom experiences scores. Given that the patients in the Low and Mid 
groups were more likely to be employed than those in the High group, 
the severity of the illness may have affected the employment prospects of 
the patients with heart failure. 
We found that the patients with high NT-proBNP levels were more 
likely to have arrhythmias, which might be attributed to the irregular 
ventricular rhythms and the pathophysiology of atrial fibrillation (AF) 
that includes hypertrophy, fibrosis, and inflammation in patients with 
arrhythmias [24]. The findings from a meta-analysis showed that pa-
tients with AF had higher baseline NT-proBNP levels and that NT-
proBNP could be a biomarker for predicting the recurrence of AF [24]. 
AF is the most common complex arrhythmia, and it is associated with 
increases in morbidity from stroke and heart failure, a poor prognosis, 
and an increase in mortality [25]. Accordingly, treatment strategies for 
patients with AF and concomitant heart failure focus on preventing 
thromboembolism and rhythm control. 
Patients with heart failure and preserved LVEFs are generally consid-
ered to have better prognoses than those patients with reduced LVEFs. 
However, a recent study reported that mortality is not necessarily low in 
patients with acute decompensated heart failure and preserved LVEFs, 
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and that it appears to depend on the NT-proBNP levels [26]. Most stud-
ies have focused on left ventricular (LV) systolic dysfunction that is as-
sessed by means of an impaired ejection fraction (EF). However, the in-
dependent association between the NT-proBNP level and the LV dia-
stolic function that was determined in the present study suggests that LV 
diastolic dysfunction is a major determinant of elevated NT-proBNP 
levels in patients with preserved EFs [27]. Therefore, it is necessary to 
consider the LV diastolic function in addition to the LVEF to precisely 
assess heart function. 
Elevated NT-proBNP levels are associated with comorbidities that in-
clude chronic renal failure, type 2 diabetes, anemia, and acute coronary 
syndrome [28, 29]. In this study, the most frequent comorbidity was dia-
betes, and patients in the Low group (NT-proBNP < 380 mg/mL) were 
less likely to have comorbidities compared with the patients in the High 
group. The findings from several studies have shown that health care 
providers must consider underlying diseases that include diabetes, renal 
failure, and right ventricular dysfunction secondary to chronic pulmo-
nary disease or acute pulmonary embolism, in patients with NT-proB-
NP concentrations that are between 100 pg/mL and 500 pg/mL [29]. 
The physical symptom experiences score was significantly associated 
with the NT-proBNP levels. We were unable to identify any studies that 
had directly addressed the relationships between physical symptom ex-
periences and NT-proBNP. Moreover, studies that have investigated tai-
lored interventions based on symptom experiences are sparse, which 
suggests that further studies are warranted to measure these factors and 
develop individualized interventions.
One randomized controlled trial compared NT-proBNP-guided care 
with standard care management, that is, without NT-proBNP guidance, 
in patients with heart failure. In the NT-proBNP-guided care arm, an 
additional goal was to lower and sustain the NT-proBNP levels, and ad-
ditional clinic visits and medication adjustments occurred. This study’s 
findings suggested that serial changes in the NT-proBNP levels were a 
risk for adverse outcomes, and that NT-proBNP-assisted treatments 
were associated with improvements in the clinical outcomes [22]. An-
other study’s findings showed that NT-proBNP-guided therapy was safe 
in elderly and highly comorbid patients [30]. This could be attributed to 
the more intense medical therapy for heart failure that was administered 
to the NT-proBNP-guided group. Further studies are needed to investi-
gate whether treatment and nursing guidance based on the NT-proBNP 
levels help to improve outcomes in a way that is more specifically suited 
to the individual needs of the patients. Longitudinal studies are needed 
to determine whether self-care influences heart failure biomarkers.
The present study has some limitations. First, the findings from this 
study cannot be generalized, because the research was based on conve-
nience sampling from patients at a single hospital, and most of the pa-
tients were outpatients with minor symptoms. Therefore, similar studies 
in patients with different heart failure severities are required in the fu-
ture. Second, the patients were enrolled over a relatively short period of 
time and the influence of seasonal variations on the symptoms of heart 
failure was not considered. Third, this study did not measure other heart 
failure biomarkers and psychological factors; hence, further research 
must be undertaken that includes psychological factors. Fourth, we 
could not consider age, sex, or renal function when the NT-proBNP 
groups were defined, because of the small number of patients, and this 
may have led to false-positive or false-negative results. 
CONCLUSION
Compared with the patients with high NT-proBNP levels, those with 
low NT-proBNP levels had significantly lower physical symptom experi-
ences scores. More patients with low and mid NT-proBNP levels were 
likely to be employed compared with the patients with high NT-proBNP 
levels. Patients with low NT-proBNP levels had higher LVEFs and were 
less likely to have arrhythmias and comorbidities. These findings sug-
gest that health care providers should understand individual patients’ 
clinical factors in order to assess the severity of the heart failure. 
Importantly, individualizing treatment approaches based on the sever-
ity of the heart failure in patients is necessary, because the results from the 
current study have demonstrated that the patients with more severe heart 
failure had higher physical symptom experiences scores. Further studies 
are warranted to investigate whether nursing guidance using biomarkers, 
including NT-proBNP, which is more specifically suited to the needs of 
individual patients, can help to improve outcomes. The results from this 
study may provide a scientific basis for nursing intervention in the future 
that accounts for the characteristics of patients with heart failure.
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